WeiniCom is a Chinese herbal compound. The purposes of this double blind study were to evaluate (1) the efficacy of WeiniCom in reducing acute
opioid withdrawal symptoms and craving, and (2) the side effects of WeiniCom, in each instance by comparing WeiniCom with
buprenorphine, an established
opioid detoxification treatment agent. Forty-two
heroin addicts meeting the criteria of dependence in DSM-IV were randomly assigned to two treatment groups: a WeiniCom group (21 cases), and a
buprenorphine group (21 cases). The
Withdrawal Symptom Rating Scale and the Craving Rating Scale were employed to assess acute
withdrawal symptoms and craving for
heroin, and the Side Effects Rating Scale was used to measure side effects in the 14-treatment period. Both the WeiniCom and
buprenorphine treatments are well-tolerated and very safe. Overall, the relief from
opioid withdrawal symptoms and craving was better in the WeiniCom group than in the
buprenorphine group. The rate of reduction in the severity of the
withdrawal symptoms was faster in the WeiniCom group than in the
buprenorphine group. By day nine to 10, the WeiniCom group showed very few
withdrawal symptoms. In contrast, from day five on, the
buprenorphine group continued to report relatively high scores for
withdrawal symptoms and craving. WeiniCom demonstrated positive effects quickly, and required a shorter treatment period to achieve a desired degree of elimination of acute
withdrawal symptoms and craving.